Wedbush Has Bullish Forecast for ZNTL FY2024 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Stock analysts at Wedbush upped their FY2024 EPS estimates for shares of Zentalis Pharmaceuticals in a research note issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now expects that the company will earn ($2.33) per share for the year, up from their previous forecast of ($2.83). Wedbush has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($3.02) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.69) EPS, Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.48) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($1.67) EPS and FY2028 earnings at ($0.88) EPS.

Several other research analysts also recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, September 16th. Finally, Guggenheim reduced their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Stock Down 12.2 %

Shares of NASDAQ ZNTL opened at $3.47 on Friday. The firm’s 50-day simple moving average is $3.42 and its 200 day simple moving average is $5.46. The company has a market cap of $247.29 million, a price-to-earnings ratio of -1.39 and a beta of 1.74. Zentalis Pharmaceuticals has a 12-month low of $2.66 and a 12-month high of $18.07.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Erste Asset Management GmbH acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $37,000. Paloma Partners Management Co acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $37,000. Anfield Capital Management LLC acquired a new stake in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $40,000. Aigen Investment Management LP acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $41,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Zentalis Pharmaceuticals during the 3rd quarter worth approximately $48,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.